Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIO752 in Progressive Supranuclear Palsy
NCT07498426Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Jun 2026
- Primary completion
- Jul 2029
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in progressive supranuclear palsy (PSP) comparing NIO752 with Placebo (2 arms). Primary endpoint: Modified Progressive Supranuclear Palsy Rating Scale 10-item at 72 weeks. Started Jun 2026; status: recruiting.
02
Drugs
NIO752
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT07498426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07498426.